Pay in 4 interest-free payments of $5.35 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
A report published in January 2025 by the US Office of Inspector General identified significant flaws in accelerated approval processes for three drugs (Biogens Aduhelm/aducanumab, Sareptas Exondys/eteplirsen, and Covis Pharma Groups Makena/hydroxyprogesterone caproate), raising questions over the effectiveness and consistency of the fast track pathway
PubMed laboratory research record [PMID: 37513889] PubMed record related to this compound for laboratory literature review
Through patent term extensions and follow-on patenting, BMS and Pfizer have engineered an estimated $50.7 billion in additional U.S
On the legal side, they allege that the companies failed to properly warn patients of the risks
Unless stated otherwise, PSCs were preincubated in DMEM containing 10% FBS and 5.5 mM glucose for 24 h
US$ 20.68
US$ 24.99
US$ 25.76
US$ 24.74
US$ 20.32
US$ 25.42
US$ 20.00
